Lead Product(s) : AGMB-129
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Agomab Reports Positive Phase 2a Results for AGMB-129 in Crohn’s Disease
Details : AGMB-129 is an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-β RI or ALK5), being studied for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : AGMB-129
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Filgotinib
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : Filgotinib
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable